Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sickle cell trait revisited.

D R Harkness1

  • 1Department of Medicine, University of Wisconsin Medical School, Madison 53792.

The American Journal of Medicine
|September 1, 1989
PubMed
Summary
This summary is machine-generated.

Genetic factors may explain why most people with sickle cell trait (SCT) have no adverse effects. Alpha-thalassemia might protect against SCT complications like splenic infarction.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hb Sun Prairie or alpha(2)130(H13)Ala----Pro beta 2, a new unstable variant occurring in low quantities.

Hemoglobin·1990
Same author

Two successful pregnancies in a woman with chronic thrombotic thrombocytopenic purpura treated by plasma infusion.

American journal of hematology·1984
Same author

Studies on avian erythrocyte metabolism. XII. The synthesis and degradation of inositol pentakis (dihydrogen phosphate).

Poultry science·1982
Same author

Regulation of hemoglobin function and whole blood oxygen affinity by carbon dioxide and pH in the loggerhead (Caretta caretta) and green sea turtle (Chelonia mydas mydas).

Hemoglobin·1982
Same author

Hazard of platelet transfusion in thrombotic thrombocytopenic purpura.

JAMA·1981
Same author

Studies on avian erythrocyte metabolism: purification and properties of myo-inositol 1-phosphatase form chick erythrocytes.

Archives of biochemistry and biophysics·1981
Same journal

Mineralocorticoid Antagonists for Post-MI HFpEF: Plausible Biology Meets Low Residual Risk?

The American journal of medicine·2026
Same journal

GLP-1 Receptor Agonists and Age-related Macular Degeneration Risk in Diabetes or Non-diabetic Obesity: A Retrospective Cohort Study.

The American journal of medicine·2026
Same journal

Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

The American journal of medicine·2026
Same journal

Cave Canem - Beware of the Dog.

The American journal of medicine·2026
Same journal

Risk Factors for 30-day Hospital Readmission After Hospital-at-Home Treatment of Acute Pyelonephritis.

The American journal of medicine·2026
Same journal

Mesenteric panniculitis.

The American journal of medicine·2026
See all related articles

Area of Science:

  • Genetics
  • Hematology
  • Molecular Biology

Background:

  • Sickle cell disease (SCD) severity varies due to genetic factors.
  • Alpha-thalassemia can reduce SCD complications, but its role in sickle cell trait (SCT) is unclear.
  • Genetic variations in the beta-globin cluster affect Hb F levels and SCD severity.

Purpose of the Study:

  • To investigate potential genetic factors influencing adverse outcomes in individuals with sickle cell trait.
  • To explore whether alpha-thalassemia offers protection against SCT-related morbidities.

Main Methods:

  • Literature review on SCT complications and associated genetic factors.
  • Analysis of reported associations between SCT, specific complications, and demographic factors.

Related Experiment Videos

Main Results:

  • Few individuals with SCT experience adverse effects, but the reasons remain largely unknown.
  • Splenic infarction in SCT predominantly affects males and Caucasians.
  • Limited evidence suggests higher Hb S levels may correlate with splenic infarction, hematuria, and reduced renal function, potentially indicating a protective role for alpha-thalassemia.

Conclusions:

  • Genetic factors likely influence SCT clinical outcomes.
  • Alpha-thalassemia may be protective against certain SCT complications.
  • Further detailed reporting of genetic and biochemical data is needed to understand SCT risks in specific subpopulations.